Unexpectedly, the stratified analysis indicated that patients with ER+PR+ tumors in the 50 to 80 mm groups experienced similar survival rates, whereas ER−PR− patients experienced increased breast cancer-specific mortality (BCSM) as tumor size increased throughout all size categories (P < 0.001). This evidence concerns the gene PGR and breast carcinoma.